×

Trinity Biotech Announces Results for Q4 and Fiscal Year 2015

DUBLIN, March 03, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for fiscal year 2015 and the quarter ended December 31, 2015. The Company also announced that it is suspending its annual dividend and initiating a share buyback program.

Fiscal Year 2015 Results

Total revenues for fiscal year 2015 were $100.2m versus $104.9m in 2014, a decrease of 4.5% year on year. This was due to the impact of the strengthening US dollar on the Company’s foreign currency denominated revenues. Other factors included lower Lyme sales due to weather related factors and unusually low HIV sales in Q2. These were partly offset by underlying growth in Premier and Immco revenues for the year.

Full Year
2014
Full Year
2015
Full Year
2015 vs 2014
US$’000US$’000%
Point-of-Care20,03618,810 (6.1%)
Clinical Laboratory84,83581,385 (4.1%)
Total104,871100,195 (4.5%)

Point-of-care revenues decreased from $20.0m in 2014 to $18.8m in 2015, which represents a decrease of 6.1%. This was due to lower HIV sales in Africa in Q2, due to unusual ordering patterns. These revenues immediately rebounded in Q3 and Q4 to normal levels.

Meanwhile, Clinical Laboratory revenues were $81.4m, a decrease of 4.1% versus 2014. The impact of the abovementioned strengthening of the dollar was largely confined to Clinical Laboratory revenues. In particular, the weakness of the Euro, Brazilian Real, Canadian dollar and Sterling, all of which represent significant currencies in which the Company invoices sales, resulted in a reduction in our US dollar denominated revenues. This was accentuated by weakness in the currencies of other countries such as Turkey, Russia and a number of South American countries where the Company invoices in US dollars. In such countries the dollar’s strength served to erode our competitiveness, which had a detrimental effect on our revenues.

The other key financial results for 2015 were as follows:

  • Operating profit for the year was $13.4m which represents an operating margin of 13.4%.
  • Profit after tax for the year was $21.8m though this includes non-cash financial income of $12.5m recognised in relation to the Company’s convertible loan notes. Excluding this, profit after tax would have been $9.3m compared with $17.2m in 2014.
  • Basic EPS for the year was 94.1 cents (40.2 cents excluding the impact of non-cash financial income) versus 75.7 cents in 2014.
  • Diluted EPS was 46.2 cents compared to 72.6 cents in 2014.

The effective tax charge for the year (which excludes the impact of non-cash financial income) was 10.4%. This low effective rate of tax is due to the competitive corporation tax rate in Ireland and the availability of research and development tax credits in a number of jurisdictions.

EBITDA before share option expense for the year was $20.7m.

Quarter 4 Results

Total revenues for Q4, 2015 were $24.9m which compares to $26.7m in Q4, 2014, a decrease of 6.5%.

2014
Quarter 4
2015
Quarter 4
Increase/
(decrease)
US$’000US$’000%
Point-of-Care5,4515,436 (0.3%)
Clinical Laboratory21,22919,501 (8.1%)
Total26,68024,937 (6.5%)

Point-of-Care revenues for Q4, 2015 were broadly flat compared to Q4, 2014.

Clinical Laboratory revenues decreased from $21.2m to $19.5m, a decrease of 8.1% compared to Q4, 2014, a decrease which is largely due to the impact of exchange rate movements.

Gross margins for the quarter were 43.2%, and this is consistent with Q4 having the lowest gross margin in the year, due to seasonality of certain products. This is lower than the gross margin noted in Q4, 2014 of 47.5%, largely reflecting the impact of foreign currency movements.

Research and Development expenses were $1.5m. Selling, General and Administrative (SG&A) expenses decreased from $7.2m to $6.0m also partly due to foreign currency movements.

The combination of lower revenues and gross margins resulted in a reduction in operating profit from $4.3m to $3.1m. Meanwhile, profit after tax for the quarter was $2.8m, which represents an EPS for the quarter of 12.1 cents or 10.5 cents on a fully diluted basis. EBITDA before share option expense for the quarter was $4.8m.

Cardiac Update

In December, 2015 we submitted our 510(k) application for our high sensitivity cardiac Troponin-I assay and Meritas Point-of-Care Analyzer to the FDA. The application was supported by three clinical studies:

  • determination of the 99th percentile Upper Reference Limit;
  • point-of-care precision performance; and
  • the validation of clinical performance of the Meritas system with subjects presenting to Emergency Departments with symptoms suggestive of Acute Coronary Syndrome (ACS).

In the ACS clinical study, we enrolled subjects at 14 different sites in the USA. Results were adjudicated by a panel of cardiologists according to the Third Universal Definition of Myocardial Infarction (MI), which includes both Type-I and Type-II MI subjects. We were pleased to report sensitivity at admission of 78% for plasma and 66% for whole blood. These results are better than we obtained with the clinical studies supporting the test’s CE Mark. The 510(k) application is currently under FDA review.

Clinical trials are currently in progress for our second cardiac marker assay, B-type Natriuretic Protein (BNP). We have 10 clinical sites that are actively enrolling and to date we have obtained approximately 50% of the patient samples we require. Enrollment is expected to be completed in Q2, 2016, and we are anticipating submission of our BNP 510(k) application to the FDA in Q3, 2016.

Share Buyback and Suspension of Dividend

The Company’s Board of Directors has authorized the commencement of a share repurchase program. Based on a resolution passed at its most recent AGM, the Company is currently authorized to repurchase up to 10% of its own shares (approximately 2.3m ADRs). The Company’s ability to buy back shares will be determined by available liquidity and general market conditions and will be carried out in accordance with applicable securities laws and regulations.

In conjunction with its initiation of a share repurchase program, the Company has decided to suspend the payment of annual dividends. It is felt that given the Company’s current share price, share repurchases represent a better deployment of capital.

Comments

Commenting on the results, Kevin Tansley, Chief Financial Officer, said “Revenues for Q4, 2015 were $24.9m, which resulted in an operating profit of $3.1m and profit after tax of $2.8m. This equates to a basic EPS of 12.1 cents or 10.5 cents on a fully diluted basis.

Total revenues in 2015 decreased from $104.9m to $100.2m and this decrease was effectively driven by exchange rate movements. These exchange rate movements also contributed to a 2% reduction in gross margins. As a direct result, operating profits for the year were $13.4m, $4.6m lower than in 2014. In addition, we incurred interest charges of $3.5m on our convertible loan notes which were issued during the year. Overall profit for the year was $21.8m, though if we were to exclude the non-cash income recognized on the convertible loan notes the profit for the year would have been $9.3m.”

Ronan O’Caoimh, CEO of Trinity said “During 2015 we operated in a very challenging economic environment. The strength of the US dollar against a range of currencies had a very significant adverse impact on our foreign currency denominated revenues. Meanwhile, in many of the countries where we actually sell in US dollars, the strength of the dollar negatively impacted on our competitiveness resulting in a knock-on effect on both revenues and margins.

We announced the submission of our high sensitivity cardiac Troponin-I assay and Meritas Point-of-Care Analyzer to the FDA in December, 2015. This is the culmination of over three years work completing the development of both the test and associated analyzer as well as running extensive clinical trials in the USA. We were very pleased with the data that was submitted and the FDA is currently reviewing the submission. We expect to be liaising with them closely in the months ahead as the review process continues. Meanwhile, the trials for the second test on the Meritas platform, BNP, are progressing well and we expect to submit this to the FDA in Q3, 2016.

Today, we are also announcing that we are initiating a share buyback program. At our current share price and in the absence of suitable acquisition targets at present, we believe that buying Trinity’s shares constitutes a sensible use of capital. At the same time, we have decided to suspend our annual dividend payment. We feel that given our size, level of R&D expenditure and the stage of the Company’s development it is not appropriate to be paying dividends.”

Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Trinity Biotech plc
Consolidated Income Statements
(US$000’s except share data) Three Months
Ended
Dec 31,
2015
(unaudited)
Three Months
Ended
Dec 31,
2014
(unaudited)
Year
Ended
Dec 31,
2015
(unaudited)
Year
Ended
Dec 31,
2014
(unaudited)
Revenues 24,937 26,680 100,195 104,871
Cost of sales (14,170) (14,014) (53,950) (54,524)
Gross profit 10,767 12,666 46,245 50,347
Gross profit % 43.2% 47.5% 46.2% 48.0%
Other operating income 65 85 288 424
Research & development expenses (1,508) (961) (5,068) (4,290)
Selling, general and administrative expenses (6,009) (7,238) (26,475) (26,964)
Indirect share based payments (184) (255) (1,541) (1,478)
Operating profit 3,131 4,297 13,449 18,039
Financial income 132 48 431 96
Financial expenses (1,189) (34) (3,483) (69)
Non-cash financial income 975 - 12,480 -
Net financing (expense) / income (82) 14 9,428 27
Profit before tax 3,049 4,311 22,877 18,066
Income tax expense (223) (187) (1,081) (853)
Profit for the period 2,826 4,124 21,796 17,213
Earnings per ADR (US cents) 12.1 18.0 94.1 75.7
Earnings per ADR excluding non-cash financial income (US cents) 8.0 18.0 40.2 75.7
Diluted earnings per ADR (US cents) 10.5 17.6 46.2 72.6
Weighted average no. of ADRs used in computing basic earnings per ADR 23,259,669 22,916,417 23,161,773 22,749,726
Weighted average no. of ADRs used in computing diluted earnings per ADR 28,690,599 23,482,268 27,407,793
23,717,747


Trinity Biotech plc
Consolidated Balance Sheets
Dec 31,
2015
US$ ‘000
(unaudited)
Sept 30,
2015
US$ ‘000
(unaudited)
Dec 31,
2014
US$ ‘000
(unaudited)
ASSETS
Non-current assets
Property, plant and equipment 20,659 19,198 17,877
Goodwill and intangible assets 161,324 156,326 145,024
Deferred tax assets 12,792 10,370 9,798
Other assets 954 1,040 1,091
Total non-current assets 195,729 186,934 173,790
Current assets
Inventories 35,125 36,882 33,517
Trade and other receivables 25,602 27,153 26,080
Income tax receivable 550 119 351
Cash and cash equivalents 101,953 104,289 9,102
Total current assets 163,230 168,443 69,050
TOTAL ASSETS 358,959 355,377 242,840
EQUITY AND LIABILITIES
Equity attributable to the equity holders of the parent
Share capital 1,220 1,216 1,204
Share premium 15,526 14,560 12,422
Accumulated surplus 201,951 198,882 183,375
Other reserves (4,809) (3,661) (26)
Total equity 213,888 210,997 196,975
Current liabilities
Income tax payable 1,163 951 785
Trade and other payables 18,874 18,694 21,196
Provisions 75 75 75
Total current liabilities 20,112 19,720 22,056
Non-current liabilities
Exchangeable senior note payable 98,044 99,069 -
Other payables 2,096 3,569 2,370
Deferred tax liabilities 24,819 22,022 21,439
Total non-current liabilities 124,959 124,660 23,809
TOTAL LIABILITIES 145,071 144,380 45,865
TOTAL EQUITY AND LIABILITIES 358,959 355,377 242,840


Trinity Biotech plc
Consolidated Statement of Cash Flows
(US$000’s)Three Months
Ended
Dec 31,
2015
(unaudited)
Three Months
Ended
Dec 31,
2014
(unaudited)
Year
Ended
Dec 31,
2015
(unaudited)
Year
Ended
Dec 31,
2014
(unaudited)
Cash and cash equivalents at beginning of period 104,289 8,949 9,102 22,317
Operating cash flows before changes in working capital 5,574 5,048 19,853 22,027
Changes in working capital 234 3,596 (7,157) (6,512)
Cash generated from operations 5,808 8,644 12,696 15,515
Net Interest and Income taxes received/(paid) 79 (53) (361) 237
Capital Expenditure & Financing (net) (5,980) (8,438) (21,604) (23,937)
Free cash flow (93) 153 (9,269) (8,185)
Payment of HIV-2 licence fee - - (1,112) -
30 year Convertible Note proceeds, net of fees (45) - 110,529 -
30 year Convertible Note interest payment (2,198) - (2,198) -
Dividend payment - - (5,099) (5,030)
Cash and cash equivalents at end of period 101,953 9,102 101,953 9,102


Contact: Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: kevin.tansley@trinitybiotech.com Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700

Source:Trinity Biotech plc